Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials

Background Supportive care interventions used to manage chemotherapy-induced myelosuppression (CIM), including granulocyte colony-stimulating factors (G-CSFs), erythropoiesis-stimulating agents (ESAs), and red blood cell (RBC) transfusions, are burdensome to patients and associated with greater cost...

Descripción completa

Detalles Bibliográficos
Autores: Ferrarotto, R, Anderson, I, Medgyasszay, B, Garcia-Campelo, MR, Edenfield, W, Feinstein, TM, Johnson, JM, Kalmadi, S, Lammers, PE, Sanchez-Hernandez, A, Pritchett, Y, Morris, SR, Malik, RK, Csoszi, T
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Fundación del Hospital Provincial de Castellón (FHPC)
Repositorio:r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
OAI Identifier:oai:fhpc.fundanetsuite.com:p1330
Acceso en línea:https://fhpc.fundanetsuite.com/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1330
Access Level:acceso abierto
Palabra clave:anemia
erythropoiesis-stimulating agent
granulocyte colony-stimulating factor
neutropenia
red blood cell transfusion
trilaciclib
id ES_6ce5e12f3f4b0607ef0056eecb08fdc1
oai_identifier_str oai:fhpc.fundanetsuite.com:p1330
network_acronym_str ES
network_name_str España
repository_id_str
spelling Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trialsFerrarotto, RAnderson, IMedgyasszay, BGarcia-Campelo, MREdenfield, WFeinstein, TMJohnson, JMKalmadi, SLammers, PESanchez-Hernandez, APritchett, YMorris, SRMalik, RKCsoszi, Tanemiaerythropoiesis-stimulating agentgranulocyte colony-stimulating factorneutropeniared blood cell transfusiontrilaciclibBackground Supportive care interventions used to manage chemotherapy-induced myelosuppression (CIM), including granulocyte colony-stimulating factors (G-CSFs), erythropoiesis-stimulating agents (ESAs), and red blood cell (RBC) transfusions, are burdensome to patients and associated with greater costs to health care systems. We evaluated the utilization of supportive care interventions and their relationship with the myeloprotective agent, trilaciclib. Methods Data were pooled from three independent randomized phase 2 clinical trials of trilaciclib or placebo administered prior to chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). The impact of supportive care on the duration of severe neutropenia (DSN), occurrence of severe neutropenia (SN), and occurrence of RBC transfusions on/after week 5 was analyzed across cycles 1-4. Concordance and association between grade 3/4 anemia, RBC transfusions on/after week 5, and ESA administration was also evaluated. Results The use of G-CSFs, ESAs, or RBC transfusions on/after week 5 was significantly lower among patients receiving trilaciclib versus placebo (28.5% vs. 56.3%, p < 0.0001; 3.3% vs. 11.8%, p = 0.0254; and 14.6% vs. 26.1%, p = 0.0252, respectively). Compared with placebo, trilaciclib significantly reduced DSN and SN, irrespective of G-CSF administration. RBC transfusions and ESAs were most often administered in patients with grade 3/4 anemia; however, patients typically received RBC transfusions over ESA administration. Conclusions By improving CIM and reducing the need for associated supportive care, trilaciclib has the potential to reduce the burden of myelosuppression on patients receiving myelosuppressive chemotherapy for the treatment of ES-SCLC. Trial registration ClinicalTrials.gov (NCT02499770; NCT03041311; NCT02514447).John Wiley and Sons Ltd2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fhpc.fundanetsuite.com/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1330Cancer MedicineISSN: 20457634reponame:r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellóninstname:Fundación del Hospital Provincial de Castellón (FHPC)Inglésinfo:eu-repo/semantics/openAccessoai:fhpc.fundanetsuite.com:p13302026-06-22T12:44:17Z
dc.title.none.fl_str_mv Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
title Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
spellingShingle Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
Ferrarotto, R
anemia
erythropoiesis-stimulating agent
granulocyte colony-stimulating factor
neutropenia
red blood cell transfusion
trilaciclib
title_short Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
title_full Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
title_fullStr Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
title_full_unstemmed Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
title_sort Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
dc.creator.none.fl_str_mv Ferrarotto, R
Anderson, I
Medgyasszay, B
Garcia-Campelo, MR
Edenfield, W
Feinstein, TM
Johnson, JM
Kalmadi, S
Lammers, PE
Sanchez-Hernandez, A
Pritchett, Y
Morris, SR
Malik, RK
Csoszi, T
author Ferrarotto, R
author_facet Ferrarotto, R
Anderson, I
Medgyasszay, B
Garcia-Campelo, MR
Edenfield, W
Feinstein, TM
Johnson, JM
Kalmadi, S
Lammers, PE
Sanchez-Hernandez, A
Pritchett, Y
Morris, SR
Malik, RK
Csoszi, T
author_role author
author2 Anderson, I
Medgyasszay, B
Garcia-Campelo, MR
Edenfield, W
Feinstein, TM
Johnson, JM
Kalmadi, S
Lammers, PE
Sanchez-Hernandez, A
Pritchett, Y
Morris, SR
Malik, RK
Csoszi, T
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv anemia
erythropoiesis-stimulating agent
granulocyte colony-stimulating factor
neutropenia
red blood cell transfusion
trilaciclib
topic anemia
erythropoiesis-stimulating agent
granulocyte colony-stimulating factor
neutropenia
red blood cell transfusion
trilaciclib
description Background Supportive care interventions used to manage chemotherapy-induced myelosuppression (CIM), including granulocyte colony-stimulating factors (G-CSFs), erythropoiesis-stimulating agents (ESAs), and red blood cell (RBC) transfusions, are burdensome to patients and associated with greater costs to health care systems. We evaluated the utilization of supportive care interventions and their relationship with the myeloprotective agent, trilaciclib. Methods Data were pooled from three independent randomized phase 2 clinical trials of trilaciclib or placebo administered prior to chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). The impact of supportive care on the duration of severe neutropenia (DSN), occurrence of severe neutropenia (SN), and occurrence of RBC transfusions on/after week 5 was analyzed across cycles 1-4. Concordance and association between grade 3/4 anemia, RBC transfusions on/after week 5, and ESA administration was also evaluated. Results The use of G-CSFs, ESAs, or RBC transfusions on/after week 5 was significantly lower among patients receiving trilaciclib versus placebo (28.5% vs. 56.3%, p < 0.0001; 3.3% vs. 11.8%, p = 0.0254; and 14.6% vs. 26.1%, p = 0.0252, respectively). Compared with placebo, trilaciclib significantly reduced DSN and SN, irrespective of G-CSF administration. RBC transfusions and ESAs were most often administered in patients with grade 3/4 anemia; however, patients typically received RBC transfusions over ESA administration. Conclusions By improving CIM and reducing the need for associated supportive care, trilaciclib has the potential to reduce the burden of myelosuppression on patients receiving myelosuppressive chemotherapy for the treatment of ES-SCLC. Trial registration ClinicalTrials.gov (NCT02499770; NCT03041311; NCT02514447).
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fhpc.fundanetsuite.com/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1330
url https://fhpc.fundanetsuite.com/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1330
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv John Wiley and Sons Ltd
publisher.none.fl_str_mv John Wiley and Sons Ltd
dc.source.none.fl_str_mv Cancer Medicine
ISSN: 20457634
reponame:r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
instname:Fundación del Hospital Provincial de Castellón (FHPC)
instname_str Fundación del Hospital Provincial de Castellón (FHPC)
reponame_str r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
collection r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410301271605248
score 15,812429

Similares en LA Referencia